PLAINSBORO, N.J., Jan. 28, 2025 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic ® to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD ...

Jan 28, 2025 · Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks...

Jan. 29, 2025 -- The FDA has approved Novo Nordisk's diabetes drug Ozempic to help reduce the risk of worsening kidney disease, kidney failure, and heart-related death in adults with type 2...

Jan 28, 2025 · The approval was based on data from a late-stage study, which showed that Ozempic helped cut the risk of death from chronic kidney disease and major cardiac events by 24%, the company said.

Jan 28, 2025 · The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney ...

Jan 29, 2025 · The FDA has approved Novo Nordisk’s Ozempic (semaglutide) as the first and only GLP-1 receptor agonist (GLP-1 RA) indicated to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 …

May 24, 2024 · Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. (Funded by Novo...

Jun 24, 2024 · Semaglutide 1 mg demonstrated a statistically significant and superior reduction of 24% in the risk of kidney disease-related events vs. placebo in adults with type 2 diabetes and chronic kidney disease. Based on FLOW trial data, Novo Nordisk submitted a label extension application for Ozempic®, which has been accepted for review by the FDA.

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

Jan 28, 2025 · The FDA approved Ozempic to cut the risk of kidney disease worsening, kidney failure and death in diabetes patients with chronic kidney disease. When Novo Nordisk unveiled kidney outcomes data for ...